FL
Insider
Fairmount Funds Management LLC
DirectorFairmount Funds Management LLC (Director) filed 8 Form 4 reports as a reporting entity in the trailing twelve months (4 purchases, 4 sales), most often in Cogent Biosciences, Inc. (COGT). Across 4 priced purchase filings, the average 21-session return was -7.3% from execution and -3.8% from disclosure (delay-adjusted; derived). The largest single filing was $399.7M of SYRE (4,684,781 sh × $85.31, as filed), executed Jun 23. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-7.3%
avg across 4 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-3.8%
same 4 filings, from disclosure
Filings, ttm
8
4 buys · 4 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.1B
shares × price, as filed
Last traded
Jul 16
Filed Jul 20
Median ADV $84.0M across their filed names
Impact on $10,000 · 12M
$10,475 (+4.8%)
S&P 500 $10,907 (+9.1%) · 4.3 pts behind
Fairmount Funds Management LLC
S&P 500
Derived: compounded across filings from disclosure dates · past 12 months
Open performance→Volume by month
Buys $94.6M
Sells $1.1B
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
8 filings
Sector per market data · by filing · past 12 months
Most traded names
COGTRecent filings
VRDNPURCHASE
Viridian Therapeutics, Inc.
View filing →
$10.0M454,545 sh × $22.00
Exec Oct 23 2025
Filed Oct 27 2025 · 4:30 PM ET ZBIOPURCHASE Zenas BioPharma, Inc. View filing → $6.0M
316,219 sh × $19.00
Exec Oct 7 2025
Filed Oct 9 2025 · 4:15 PM ET COGTPURCHASE Cogent Biosciences, Inc. View filing → $25.0M
2,777,777 sh × $9.00
Exec Jul 10 2025
Filed Jul 14 2025 · 5:30 PM ET